We further evaluated therapeutic potential of doxorubicin in EP300-ZNF384 positive B-ALL cells in vitro and in vivo, pointing to that targeted therapies involving anthracyclines may produce a favorable outcome in patients with EP300-ZNF384. The gene discussed is EP300; the disease is acute lymphoblastic leukemia.